Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis - PubMed
5 hours ago
- #obesity
- #cardiovascular biomarkers
- #tirzepatide
- Tirzepatide significantly improved cardiovascular risk biomarkers at 72 weeks compared to placebo across multiple pathways.
- Notable reductions included biomarkers for inflammation (e.g., high-sensitivity C-reactive protein down up to -54.6%), metabolic/adiposity/hepatic stress (e.g., leptin down up to -61.4%), and endothelial dysfunction (e.g., E-selectin down up to -26.4%).
- No consistent associations were observed with fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.
- This analysis provides a comprehensive, randomized assessment of long-term biomarker changes during tirzepatide treatment in obesity, supporting its potential cardiovascular benefits.